X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Asia

Thailand LAB INTERNATIONAL 2020 postponed to October 2020

Content Team by Content Team
6th May 2020
in Asia, Press Statements
Thailand LAB INTERNATIONAL 2020 postponed to October 2020

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

VNU Asia Pacifichas, together with the vast majority of exhibitors, decided to postpone Thailand LAB INTERNATIONAL 2020 to October 28-30, 2020. This decision has been taken mainly because of estimated travel restrictions caused by the Coronavirus (COVID-19)outbreak for the September dates.

This decision has been taken after careful consideration and in the interest of exhibitors and visitors and, above all, to protect the health of all stakeholders and attendees and guarantee a smooth and high-quality exhibition.

VNU as organizer assessed the situation and reassures the safety of our exhibitors and visitors, as well as, is committed to improve the quality of the exhibitionunder the COVID-circumstances. The majority of exhibitors and partners agreed with the organizer on the postponement of the event as being the best solution and have therefore confirmed their participation for end October 2020, trusting that the situation will improve significantly during the next few months.

Thailand LAB INTERNATIONAL 2020 is re-scheduledto October28-30,2020. Our key theme remains the same, which is to celebrate Thailand LAB’s 10th Anniversary and continue being the Collaborative Innovation Platform for Laboratory and Life Sciences Industry in Asia Pacific.

For more information please visit the official website: www.thailandlab.com

About VNU Asia Pacific

VNU Asia Pacific is part of VNU Group, a globally operating exhibition company with offices in Utrecht, Shanghai as well as in Bangkok, and consolidates the international exhibition business of Royal Dutch Jaarbeurs. In South East Asia, Jaarbeurs has formed a Joint Venture with the TCC Group, a leading corporate conglomerate in the fast-growing region. From its business hub located in Bangkok, VNU Asia Pacific covers all key exhibition markets in South East Asia. VNU Asia Pacific has a constantly expanding portfolio with currently 12 trade shows and event formats including brands from the AgriTech, Animal Husbandry, Animal Companion, Food, Life Sciences and Biotechnology industries.

Royal Jaarbeurs belongs to the top 20 exhibition organizers by revenue worldwide and operates a 100.000 square meter exhibition center in the city of Utrecht, The Netherlands. In the coming years, the company is going to invest 300 Million Euro into further expansions of its exhibition centre to continue to meet the highest technology and sustainability standards. The Asian counterpart, TCC Group, headquartered in Thailand is one of South East Asia’s leading conglomerates and most recognized corporations. TCC Group employs 60,000 employees and has an extensive service and real estate portfolio. One of its real estate highlights is the premier exhibition and conference venue in the heart of Bangkok. The Queen Sirikit National Convention Centre (QSNCC) is currently being newly built and scheduled to re-open at the end of 2022.

For more information, visit www.vnuasiapacific.com

Previous Post

Vaxart Announces Additional Positive Pre-Clinical Data for its Oral COVID-19 Vaccine Program

Next Post

Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program

Related Posts

DCS Lab Project
Asia

MGI Tech and JCBio Advance Multi-Omics with DCS Lab Project

4th September 2025
Packaging & Logistic

VarioFill: Rotzinger sets new standards with highly flexible filling and capping platform for OTC products

30th August 2025
Major Depressive Disorder
Americas

AbbVie to Acquire Gilgamesh Pharmaceuticals’ Bretisilocin, a Novel, Investigational Therapy for Major Depressive Disorder, Expanding Psychiatry Pipeline

27th August 2025
Biosimilar Ranibizumab
Asia

Lupin, Sandoz Collab to Commercialise Biosimilar Ranibizumab

18th August 2025
Schott-Testing
Press Statements

Carbon Reduced Pharmaceutical Glass: SCHOTT Melting Tank Construction Starts and External Certification for FIOLAX® Pro OCF

11th August 2025
Taiwan Grants Full Approval for NEFECON IgAN Treatment
Asia

Taiwan Grants Full Approval for NEFECON IgAN Treatment

7th August 2025
Next Post
Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program

Pfizer and BioNTech Dose First Participants in the U.S. as Part of Global COVID-19 mRNA Vaccine Development Program

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In